On June 27th, Gelunhui reported that the Danish pharmaceutical giant, Novo Nordisk, has received approval for the injection of Semaglutide, a weight-loss version used for long-term weight management, in China. Experts say that although Novo, Yingsi Semaglutide injection has been approved for weight management, it also has strict indications for use. Users must have an initial BMI value of overweight or obese, and at least one weight-related complication such as high blood sugar, hypertension, abnormal blood lipids, obstructive sleep apnea or cardiovascular disease. Experts remind that the injection of Semaglutide for weight loss has good results, but patients may experience adverse reactions such as gastrointestinal discomfort, hypoglycemia, and acute pancreatitis. Semaglutide is a prescription drug, and patients should go to the hospital for relevant checks and evaluations, and adjust the dosage reasonably under the guidance of a professional doctor.